20.1 C
New York

Tag: listing

Bitcoin Options Expire

The bitcoin and ethereum options on Deribit, one of the largest crypto derivatives exchange, expired earlier today. This month saw the largest open interest in...

Top News

The KCC Unicorn Contest Data Competition Kicked Off With Over 100 Projects Participating

The KCC Unicorn Contest Data Competition Kicked Off With Over 100 Projects Participating
The KCC Unicorn Contest is the first activity of the $500 million Ecosystem Accelerator Plan, as well as KCC’s first incentive program in 2022. Its goal is to find the best projects from various streams and channels in order to improve the on-chain ecosystem. In addition, the contest itself gives considerable financial assistance, with the […]

Cardano DEX Ravendex continues ISPO and set for 4th exchange listing

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass AdoptionThe Ravendex team has announced plans for a 4th exchange listing as the Cardano Startup’s ISPO forges ahead. Using the Cardano Proof Of Stake System, Ravendex utilized it to develop a mechanism by which ADA holders to stake their tokens on the RaveP Stake pool and they will be rewarded with Rave Tokens every five […]

Analytical Platform RaysX Will Launch the RAX Token

Dubai, UAE, Apr 19, 2022 - (ACN Newswire) - RaysX, an analytical platform that helps traders and investors to holistically analyze the cryptocurrency market and decentralized finance, will launch its own RAX token.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Early investors may have the opportunity to participate in the private sale of $RAX tokens before listing on crypto exchanges. According to the founders of the project, they only consider the RAX listing on the major crypto exchanges, including Binance. To purchase a token at a favorable price, investors and users need to fill out a whitelist.

"RAX is a native utility token of RaysX that helps developers monetize and stimulate the evolution into DeFi 2.0. It is a medium of exchange between developers and DeFi investors using Web3 applications. Third-party developers can build and deploy apps while users can use these apps by paying with RAX," said RaysX founder George Gus.

RAX token can be used in multiple cases, one of which is app deployment. This means that external app developers access ready-made modules to build and deploy their applications using RAX token. In addition, users pay external app developers for the rights to access these apps using RAX tokens. They also get access to exclusive analytics and forecasts created by analysts and seasoned traders. At the same time, DeFi investors pay transaction fees required by trading apps on RaysX platform.

About RaysX

RaysX is designed to bring together the best minds of the crypto industry to accelerate the transition to DeFi 2.0 by overcoming and breaking down the constraints that are preventing the crypto market from becoming a full-fledged alternative to traditional finance today. List of RaysX key products includes:

  • RAX Token. A native utility token of RaysX that helps developers monetize and stimulate the evolution into DeFi 2.0.
  • The environment of the external Open Source Apps for DEXs and DeFi with monetization through RAX Token.
  • The ML Prediction algorithm for deep data analytics and ranking with an open API for developers.
  • Analytics Dashboard, DEX Terminal, and marketplace for external apps.
  • RAX CryptoRank. A ranking algorithm to build a fairer rank.
  • External Apps. A marketplace for external applications that allows any developer to deploy his application to the platform and make it available to a wide range of investors and users.

Social Links
Medium: https://medium.com/@raysx
Twitter: https://twitter.com/Ray__sX
Telegram: https://t.me/Ray_sX

Media Contact
Brand: RaysX
Contact: Media team
E-mail: gg@ray.sx
Website: https://ray.sx/

SOURCE: RaysX



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

Yew Lee Pacific Group Bhd Engages M&A Securities Sdn Bhd to Manage Listing Exercise

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

KUALA LUMPUR, Apr 11, 2022 - (ACN Newswire) - Yew Lee Pacific Group Bhd (Yew Lee), an established manufacturer of industrial brushes as well as the trading of machinery parts and industrial hardware is pleased to announce that it has entered into an underwriting agreement with M&A Securities Sdn Bhd (M&A Securities) today for the Company's upcoming initial public offering (IPO) on the ACE Market of Bursa Malaysia Securities Bhd (Bursa Securities).

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Chief Operating Officer of Yew Lee, Ms. Amber Ang; Managing Director of Yew Lee, Mr. Ang Lee Leong; Managing Director of Corporate Finance of M&A Securities, Datuk Bill Tan; Deputy Head, Corporate Finance of M&A Securities Mr. Danny Wong [L-R]

The IPO exercise involves the public issue of 133.1 million shares and an offer for sale of 26.62 million shares to selected investors. From the public issue, 26.62 million shares will be made available for application by the Malaysian public via balloting; 15.97 million shares will be allocated to its eligible directors and employees (pink forms); another 23.96 million shares will be reserved for private placement to selected investors and; an allocation of 66.55 million shares will be allocated through private placement to bumiputera investors approved by the Ministry of International Trade and Industry (MITI).

Under the underwriting agreement, M&A Securities will underwrite 42.59 million shares of the total proposed issue of shares allocated to the Malaysian public and through pink forms. M&A Securities will also place out 90.51 million issue shares to selected investors and bumiputera investors approved by MITI.

Managing Director of Yew Lee, Mr. Ang Lee Leong, said: "We are delighted to be working with M&A Securities on our IPO as this underwriting agreement marks the first stage of the path towards our eventual successful listing on the ACE Market of Bursa Securities. This listing will help us to raise the capital needed for our expansion plans while at the same time, boost our brand visibility in the industrial brush industry."

Managing Director of Corporate Finance of M&A Securities, Datuk Bill Tan said, "We are pleased to be playing a key role in the IPO exercise of Yew Lee. The Company has solid experience and expertise in the production of industrial brushes with a history that goes back to the early 1990s. It has come far but we have no doubt that Yew Lee will build upon this listing to excel even further. We wish the Company well as it enters a new stage in its growth."

Yew Lee manufactures industrial brushes for a variety of industries, including glove, industrial, electrical and electronic, industrial and commercial cleaning providers as well as glass and wood producers. For the financial year ended 31 December 2020 (FY2020), Malaysia contributed 81.4% of total revenue, with Thailand contributing 6.7% and Vietnam contributing 6.2%. By industry, glove manufacturers contributed 88% to revenue in FY2020.

Yew Lee Pacific Group Bhd: https://yewlee.com.my/

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comYew Lee Pacific Group Berhad (Yew Lee), an established manufacturer of industrial brushes as well as the trading of machinery parts and industrial hardware is pleased to announce that the Company has entered into an underwriting agreement with M&A Securities Sdn Bhd (M&A Securities) today for the Company's upcoming initial public offering (IPO) on the ACE Market of Bursa Malaysia Securities Berhad (Bursa Securities).

RTO of LTKM Berhad via the Acquisition of EMS Business for RM336 Million

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

KLANG, Malaysia, Apr 8, 2022 - (ACN Newswire) - LTKM Berhad (LTKM), a leading chicken egg producer, today announced a composite proposal, chiefly to divest the Company's existing business and venture into the business of providing of electronic manufacturing services (EMS) while at the same time, rectify its non-compliance with the public spread requirement of its shares under the listing requirements of Bursa Securities Malaysia Berhad.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Chai Voon Sun, co-founder and Managing Director of Local Assembly [L] and Executive Chairman of LTKM, Datuk Tan Kok

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Wee Thian Song - Co-founder, Executive Director and Engineering Director of Local Assembly; Gurmakh Singh - Co-founder, Executive Director and General Manager of Local Assembly; Datuk Seri Chiau Beng Teik - Executive Chairman of Chin Hin Group Berhad; Chai Voon Sun - Co-founder and Managing Director of Local Assembly; Datuk Tan Kok - Executive Chairman of LTKM; Tan Kah Poh, Kenny - Independent Director of LTKM; Rahman Ali Bin Abdul Wahab - Director of Proven Venture Sdn. Bhd. [L-R]

Executive Chairman of LTKM, Datuk Tan Kok said, "At its core, the proposals seek to reward our shareholders from the proceeds of the disposal of the Company's existing poultry business while at the same time, allow them to continue participating in the new EMS business following the proposals."

"The proposed disposal comes amid the challenging operating landscape for the poultry industry brought on by overcapacity, low average selling price of eggs, high raw material prices, difficulty in controlling disease outbreaks in the farms and acute labour shortage. In relation to these challenges, we have also incurred losses in the recent financial years ended 31 March 2020 to 2021 and for the nine-month period ended 31 December 2021. This has affected our ability to pay dividends too."

"Concurrent with the proposed disposals, we believe the proposed acquisition of the EMS business is an opportunity to create value for our shareholders through a business that is viable and profitable."

Briefly, the proposals comprise the following inter-conditional steps:

1. Proposed disposal of LTKM's existing business to Ladang Ternakan Kelang Sdn Bhd (LTKSB) for a total cash disposal consideration of RM158.83 million. LTKSB, which holds 71.6% of the equity interest in LTKM, is also the holding company of LTKM;

2. Proposed special dividend and capital repayment of RM1.1098 per LTKM share totalling RM158.83 million on an entitlement date to be determined;

3. Proposed consolidation of two existing LTKM shares into one LTKM share following the proposed special dividend and capital repayment;

4. Proposed acquisition by LTKM, of 100.0% equity interest in Local Assembly Sdn Bhd (Local Assembly) from Chai Voon Sun, Gurmakh Singh a/l Ajmer Singh, Wee Thian Song, Divine Inventions Sdn Bhd and Proven Venture Sdn Bhd (Vendors) for RM336.00 million to be satisfied through cash of RM100.00 million and the issuance of 393,333,333 new LTKM shares at an issue price of RM0.60 each;

5. Proposed restricted issue of 230.00 million new LTKM shares at an indicative issue price of RM0.60 each, representing 33.1% of the enlarged share capital of LTKM after the proposals to investors to be identified;

6. Proposed exemption to the vendors and persons acting in concert from the obligation to undertake a mandatory take-over offer to acquire the remaining LTKM shares not already owned by them upon completion of the proposed acquisition; and

7. Proposed change of name to "LA Technology Berhad" from "LTKM Berhad".

The proposed acquisition will result in a significant change in LTKM's business direction from a producer of chicken eggs to becoming an EMS provider. Local Assembly, an EMS provider, will become a wholly-owned subsidiary of LTKM while the vendors of Local Assembly will become LTKM's controlling shareholders with a 56.6% equity interest in the Company following the proposed acquisition and proposed restricted issue. By virtue of his shareholding in Divine Inventions, Datuk Seri Chiau Beng Teik, the Executive Chairman of Chin Hin Group Berhad, will become a major shareholder of LTKM.

Under the proposed acquisition, the vendors have provided a profit guarantee for Local Assembly of a minimum profit after tax (PAT) of RM28.00 million for the financial year ending 31 December 2022 or not less than an aggregate of RM50.00 million PAT for both financial years ending 31 December 2022 and 2023. Based on the guaranteed PAT of RM28.00 million for the financial year ending 31 December 2022, the purchase consideration represents a price to earnings multiple of 12 times.

For Chai Voon Sun, co-founder and Managing Director of Local Assembly, the listing of Local Assembly via LTKM means a realisation of 2 decades of hardwork for him and his co-founders and a step forward in the company's journey of growth and expansion. "This transaction is a major milestone for Local Assembly. We look forward to the next phase of our corporate journey as a listed entity, which will further accelerate our growth as an EMS player, allow us to expand our customer base and product offerings and pursue more opportunities" he adds.

Local Assembly, which started operations in 2000, is a manufacturer of electronic, electrical and plastic injection moulded components, and sub-contract assembler of electrical appliances and equipment. Its principal markets are Malaysia and Singapore. For the financial year ended 31 December 2022, Local Assembly achieved PAT of RM20.06 million on the back of a revenue of RM116.35 million.

The application for the proposals is expected to be submitted to the relevant authorities by the second quarter of 2022. Subject to approvals from relevant parties including Securities Commission, Bursa Securities Malaysia Berhad as well as shareholders of LTKM, the proposals are expected to be completed in the first half of 2023.

M & A Securities Sdn Bhd is Adviser to LTKM for the proposals.

LTKM Berhad: https://www.ltkm.com.my/
LTKM Berhad: 7085 / [BURSA: LTKM] [RIC: LTKM:KL] [BBG: LTKM:MK]

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comLTKM Berhad (LTKM), a leading chicken egg producer, today announced a composite proposal, chiefly to divest the Company's existing business and venture into the business of providing of electronic manufacturing services (EMS) while at the same time, rectify its non-compliance with the public spread requirement of its shares under the listing requirements of Bursa Securities Malaysia Berhad.

Legend Capital’s Portfolio Company Recbio Lists on HKEX Successfully

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

HONG KONG, Apr 7, 2022 - (ACN Newswire) - On 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange. The listing makes Recbio "the first HPV vaccine stock in Hong Kong" and "the first novel adjuvant vaccine stock in Hong Kong". Recbio is expected to inject new vitality into the capital market in Hong Kong.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Recbio is a novel vaccine company driven by independent novel adjuvant technology. It has built a comprehensive and high-valued vaccine portfolio consisting of 12 candidates, covering cervical cancer, COVID-19, adult tuberculosis, shingles, HFMD, influenza, etc. Recbio is primarily focused on the R&D of HPV vaccine candidates. Its core product REC603, a recombinant HPV 9-valent vaccine, is currently under phase III clinical trial, and is expected to become the first approved domestic HPV 9-valent vaccine in China. In addition, Recbio has also begun to deploy in the mRNA vaccine field and is currently developing the COVID-19 mRNA vaccine.

Recbio has constructed the three core technology platforms consisting of independent novel adjuvants, protein engineering and immunological evaluation. It is one of the few companies capable of independent development of novel adjuvants and the novel adjuvants it developed have been successfully applied in various innovative vaccines such as COVID-19 vaccines, HPV vaccines and shingles vaccines.

Legend Capital led Recbio's Series B financing in 2020, through a coordinated investment of the comprehensive growth fund and the healthcare fund and re-upped on its Series C financing in 2021, marking Recbio another successful case towards Legend Capital's multi-fund coordinated investment. As the major institutional investor to Recbio, Legend Capital provides Recbio with multi-faceted support involving corporate governance, business strategy, technical route, R&D resources, management improvement and financial support.

Dr. Liu Yong, the Founder, Chairman of the Board, and General Manager of Recbi, said, "We are much appreciated Legend Capital's long-term and firm support to Recbio. As the institutional investor with the largest shareholding in the company, Legend Capital's investment philosophy of 'Business First, People Crucial' is highly compatible with our corporate culture. Legend Capital has always supported our management team in major decision-making and continued to assist in the development, becoming one of the most trusted and respected investors of Recbio. The listing is just a new chapter of Recbio, and the management team hopes to work closely with all the investors represented by Legend Capital to write a new legend!"

Hank Zhou, the Co-Chief Investment Officer of Legend Capital, said: "Congratulations to Recbio and its team led by founder Dr. Liu Yong. Liu has been engaged in vaccine research and development for over two decades, with high academic status and extensive experience in the industry. Liu's team has been deeply involved in the field of vaccine research and development for many years. Its vaccine portfolio strategically aimed at major disease and the team is actively deploying large-scale production. We admire Liu's great enthusiasm for the vaccine industry and his strong sense of responsibility and commitment. Recbio is now the leading vaccine company in China. After the successful listing, we believe that Recbio will continue to make breakthroughs in its core field of new adjuvant and vaccines to benefit more patients."

Frank Hong, the Managing Director of Legend Capital, said: "After the outbreak of the pandemic, the vaccine industry has stepped into a high-speed development stage after years of accumulation on technology and talent pool. Recbio is one of the few vaccine companies with high-quality technology platforms, which can continuously produce high-quality vaccine products to meet unmet clinical needs. We are optimistic about Recbio's future of its core pipelines, including the HPV vaccine, recombinant shingles vaccine REC610 and COVID-19 vaccine. Advanced with its disruptive technology in the field of recombinant protein vaccines, Recbio is expected to be a company with strong competitiveness in the global market."

Legend Capital has long paid close attention to investments in the field of life sciences. In addition to Recbio, there are other portfolio companies listed on A shares or H shares, including Pharmaron Inc. (300759.SZ; 03759.HK), KingMed Diagnostics (603882.SH), WuXi AppTec(603259.SH; 02359.HK), WuXi Biologics (02269.HK), Innovent Biologics (01801.HK), Berry Genomics (000710.SZ), Harbour BioMed (02142.HK), New Horizon Health (06606.HK), Chemclin Diagnostics (688468.SH), etc.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comOn 31 March 2022, Legend Capital's portfolio company Jiangsu Recbio Technology Co., Ltd. ("Recbio", stock code: 2179.HK), a leading novel vaccines company, went public on the Hong Kong Stock Exchange.
Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

YouHodler Lists ApeCoin (APE) With Limited-Time 30% Interest Rate

LAUSANNE, SWITZERLAND, Apr 5, 2022 - (ACN Newswire) - Swiss financial intermediary and FinTech platform YOUHODLER announce the listing of the popular ApeCoin (APE) to the platform. As of today, all clients can buy, exchange, trade, lend, and earn APE. Furthermore, YouHodler is offering a limited-time savings account interest rate of 30% APR for all APE deposits. These rates are available until April 30th. After that date, the interest rates will decrease to 3% APR plus compound.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

What is ApeCoin (APE)?

ApeCoin (APE) is the native governance token that powers the APE ecosystem. The APE ecosystem includes two of the most popular NFT communities, the Bored Ape Yacht Club (BAYC) and the Mutant Ape Yacht Club (MAYC).

APE is an ERC-20 utility token that aims to incentivize the decentralized community. Furthermore, ApeCoin holders are said to govern themselves and the community with the help of the ApeCoin DAO - a decentralized autonomous organization. In the DAO, ApeCoin holders can vote on the evolution of the ApeCoin ecosystem and how it should be used.

Yuga Labs, the brains behind ApeCoin, say that APE utility will soon include using it for in-game purchases, merchandise, services, and events in the metaverse and ApeCoin ecosystem. Due to the popularity of BAYC and MAYC, ApeCoin has a volatile introduction to the world. For those looking to activate their crypto portfolio and play with this volatility, visit YouHodler today.

About ApeCoin

The APE Foundation is the steward of ApeCoin. It is not an overseer, but the base layer on which ApeCoin holders in the ApeCoin DAO can build.

The Foundation facilitates decentralized and community-led governance and is designed to become more decentralized over time. It is tasked with administering the decisions of the ApeCoin DAO and is responsible for day-to-day administration, bookkeeping, project management, and other tasks that ensure the DAO community's ideas have the support they need to become a reality.

The goal of the APE Foundation is to steward the growth and development of the APE ecosystem in a fair and inclusive way. It utilizes the Ecosystem Fund, which is controlled by a multi-sig wallet, to pay its expenses as directed by the ApeCoin DAO and provides an infrastructure for ApeCoin holders to collaborate through open and permissionless governance processes.

About YouHodler

YouHodler FinTech platform is focused on crypto-backed lending with fiat (USD, EUR, CHF, GBP), crypto and stablecoin loans (USDT, USDC, TUSD, PAX, PAXG, DAI, HUSD), crypto/fiat, and crypto/crypto conversions The platform supports BTC, BCH, BNB, ETH, LTC, XLM, XRP, DASH, HT, REP, and other popular cryptocurrencies and tokens. User's digital assets are safely guarded with Ledger Vault's advanced custody and Fireblocks security options.

To learn more about YouHodler Switzerland visit youhodler-swiss.com

Community and Social Media
Twitter: https://twitter.com/youhodler
Telegram: https://t.me/youhodler_official
LinkedIn: https://www.linkedin.com/company/youhodler/
YouTube: https://www.youtube.com/channel/UC-Kxvqm8Q-l_WGxQL0VpEEQ

Contact Details:
Brand: YouHodler
Vaida Saltenyte, Head of Partnerships
vaida@youhodler.com
Website: https://www.youhodler.com/

SOURCE: YouHodler



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

Electronics Manufacturing Solutions Provider Cnergenz Berhad Enlists UOB Kay Hian Securities as Underwriter for Its Listing Exercise

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

KUALA LUMPUR, Apr 4, 2022 - (ACN Newswire) - Cnergenz Berhad (CNERGENZ), an electronics manufacturing solutions provider based in Penang, specialising in surface mount technology (SMT) catering to the electronics and semiconductor industries (E&S Industries), is pleased to announce that the Company has entered into an underwriting agreement with UOB Kay Hian Securities (M) Sdn Bhd (UOB Kay Hian) today for its upcoming initial public offering (IPO) on the ACE Market of Bursa Malaysia Securities Berhad (Bursa Securities).

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
UOB Kay Hian Securities Sdn. Bhd Chief Executive Officer Mr. David Lim; Cnergenz Berhad Chief Executive Officer Mr. Lye Yhin Choy [L-R]

The Company had obtained approval to list on the ACE Market of Bursa Securities and is targeting to launch its Prospectus in April 2022.

The IPO exercise involves the public issue of 100.0 million issue shares and an offer for sale of 50.0 million offer shares by way of private placement.

From the public issue, 25.0 million issue shares will be made available for application to the Malaysian public, 10.0 million shares will be allocated for application by eligible directors and employees as well as persons who have contributed to the success of Cnergenz Group ("Group") ("Eligible Persons"), 52.75 million shares will be reserved for private placement to identified investors and 12.25 million shares will be reserved for private placement to identified Bumiputera investors approved by the Ministry of International Trade and Industry ("MITI").

UOB Kay Hian will underwrite an aggregate of 35.0 million issue shares, comprising 25.0 million shares under the public issue and 10.0 million shares allocated to Eligible Persons as part of the underwriting agreement.

Chief Executive Officer of Cnergenz, Mr. Lye Yhin Choy, said, "This listing will enable us to strengthen our name as a leading electronics manufacturing solutions provider in Malaysia whilst deepening our presence in Thailand and Vietnam, countries which are benefitting from strong investment flows into the E&S Industries."

Chief Executive Officer of UOB Kay Hian, Mr. David Lim said, "UOB Kay Hian is pleased to be working with Cnergenz on its IPO exercise. The Company has a stellar track record and experience in the E&S Industries that dates back to 2004. We are happy to work with Cnergenz in achieving its listing goals."

Cnergenz collaborates closely with its network of over 50 suppliers to offer quality solutions for their customers, building a strong network and contributing to Cnergenz' business development and growth.

Cnergenz caters to domestic and international customers across Malaysia, Vietnam and Thailand. Cnergenz has a customer base of over 100 local and multinational companies operating within the E&S Industries, comprising integrated design manufacturers (IDMs), outsourced semiconductor assembly and test service providers (OSATs) and electronics manufacturing service providers (EMSs), some of which have been customers of Cnergenz for over 15 years.

Cnergenz Bhd: https://cnergenz.com
Cnergenz Bhd: [BURSA: CNERGENZ]

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comCNERGENZ Berhad is pleased to announce that the Company has entered into an underwriting agreement with UOB Kay Hian Securities (M) Sdn. Bhd. ("UOB Kay Hian") today for its upcoming initial public offering ("IPO") on the ACE Market of Bursa Malaysia Securities Berhad ("Bursa Securities").

Official Listing of Recbio on HKEX, Vaccine Innovation and Iteration Accelerated by Novel Adjuvant Technology

HONG KONG, Apr 1, 2022 - (ACN Newswire) - On March 31, the China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", Stock Code: 2179.HK) went public and was officially listed on the Hong Kong Stock Exchange. Assuming the Over-allotment option is not exercised, 30,854,500 H shares were issued under the Global Offering, with a price of HK$24.80 per share and proceeds up to approximately HK$765 million. The Hong Kong public Offering received an enthusiastic response from investors and was over-subscribed by more than 9.65 times. As the cornerstone investors of the Company, the cornerstone subscription ratios of Yangtze River Pharmaceutical, Harvest Global and Sequoia China exceed 50%. Previously, the Company has won the favor of many well-known investment institutions, including Legend Capital, LYFE Capital, Oriental Fortune Capital, Fer-Capital, Sequoia China, CMB International, Lake Bleu and Temasek. Having successfully listed in Hong Kong, becoming "the first HPV vaccine stock in Hong Kong" and "the first novel adjuvant vaccine stock in Hong Kong", Recbio is expected to inject new vitality into the capital market in Hong Kong.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Chart: Innovative vaccine portfolio of Recbio

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Domestic vaccine innovation and iteration accelerated by novel adjuvant technology

Vaccines are praised as the "golden track" in the medical health field. According to the Frost & Sullivan report, from 2016 to 2020, the size of the global vaccine market has increased from US$27.5 million to US$39.9 billion at a CAGR of 9.7%, while the CAGR of global pharmaceutical market was only 3.02%. China has become the second largest vaccine market globally, with the market volume increased from RMB27.1 billion in 2016 to RMB75.3 billion in 2020 at a CAGR of 29.1%.

Regarding the insufficient domestic supply of and the unmet urgent demand for novel vaccines, it has become an important part of the Development Planning of the Pharmaceutical Industry in the "14th Five-Year Plan" in China (referred as the "Plan") to promote enterprises to speed up the development of related products and to achieve product availability as soon as possible. Regarding the development of the vaccine industry, the "Plan" also states that research and development of novel vaccines (such as novel adjuvants for vaccines and mRNA vaccines) and building of industrialization capability shall be accelerated. It also emphasizes on the development of novel COVID-19 vaccines, herpes vaccines, polyvalent human papillomavirus (HPV) vaccines and other products.

As an innovative novel vaccine company, Recbio has constructed the three core technology platforms consisting of novel adjuvants, protein engineering and immunological evaluation, forming synergy in antigen design and optimization, adjuvant development and production, identification of the best combination of antigen and adjuvants. The Company has built a comprehensive and high-valued vaccine portfolio consisting of 12 candidates, covering cervical cancer, COVID-19, adult tuberculosis, shingles, HFMD, influenza etc. It covers five of the ten diseases with the greatest burden under the 2019 Global Burden of Diseases issued by the World Health Organization and disease areas of the three of the top five globally bestselling vaccine products in 2020.

Novel adjuvant for vaccines is the "bottleneck" technology of innovative vaccines. Through years of technical research, Recbio has successfully achieved independent control of all FDA-approved novel adjuvants, and is one of the few companies in the world capable of independent development of novel adjuvants. It has also successfully applied in various innovative vaccines such as COVID-19 vaccines, HPV vaccines and shingles vaccines.

A moat constructed with a rich product portfolio

HPV vaccines are one of the most commercially valuable vaccines in the world. It is expected that there will be 234 million females in China aged 9-45 unvaccinated for HPV in 2025 assuming 3 doses per person, requiring additional 702 million doses. Currently, Recbio has formed a full coverage of bivalent, quadrivalent and 9-valent vaccines and novel adjuvant upgrades in the field of HPV vaccines. The core product REC603, a recombinant HPV 9-valent vaccine is currently under phase III clinical trial, expected to become the first approved domestic HPV 9-valent vaccine. Regarding the global immunization program market, REC601, a bivalent vaccine has the potential to become one of the most popular vaccine options. At the same time, the Company is also in the process of developing second-generation HPV vaccines, namely REC604a (a quadrivalent vaccine) and REC604b (a 9-valent vaccine). Both vaccines have adopted our self-developed novel adjuvants and are expected to achieve two-shot regimens in the future. The construction of the first phase of the HPV manufacturing facility of Recbio is expected to be completed by the end of this year. By then, it will realize the designed capacity of five million doses of HPV 9-valent vaccines or 30 million doses of HPV bivalent vaccines per year. As the first cancer preventive vaccine in the world, HPV vaccines have been in shortage for a long time. With the gradual release of domestic HPV vaccines in the future and the gradual release of production capacity, domestic substitution will be accelerated.

Protein engineering, novel adjuvant and other technology are comprehensively used in ReCOV, the COVID-19 vaccine of Recbio, to thoroughly optimize the vaccine, allowing ReCOV to possess a series of comprehensive advantages, including excellent safety, strong immunogenicity, strong cross-protection effectiveness with Omicron and Delta mutant strains, easy-to-scale-up production, low production cost, high preparation stability, storage and transportation in room temperature etc. The international phase II/III clinical trials of such vaccine are currently in progress. EUA/BLA applications are estimated to be submitted in 2022. On the side of production supply, the Company has completed the construction of our GMP-standard manufacturing facility for ReCOV and obtained the drug production license in November 2021. The manufacturing facility has a total GFA of approximately 17,000 sq.m., has the potential to support an annual manufacturing capacity of 300 million doses of ReCOV and can be used to manufacture recombinant shingles vaccines.

In the field of shingles vaccines, shingles virus is dormant in almost all adults over 50 of age in China, affecting approximately 2.5 million adults in China every year. However, Shingrix is currently the only shingles vaccine approved in China. The novel adjuvant which benchmarking AS01 is adopted in REC610 of the Company, significantly improving vaccine immunogenicity, hoping to achieve domestic substitution quickly.

Recogen, our subsidiary has first achieved technology breakthrough in lyophilized mRNA vaccines. It has applied the self-developed freeze-drying technology to achieve preparation stability at 4 degrees Celsius and 25 degrees Celsius, allowing storage and transportation under general cold-chain conditions, effectively solving the current defect in availability of mRNA vaccines.

"We are glad that the Hong Kong stock IPO has been highly recognized by the capital market. The successful listing of Recbio is expected to bring more confidence to the Hong Kong 18A stock market. Thanks to all the investors for their strong support, we were able to successfully go public as originally planned in such extremely depressed environment of the Hong Kong capital market!" Regarding the listing of Recbio in Hong Kong, Dr. Liu Yong, the Founder, Chairman of the Board, and General Manager of Recbio stated that, "Against the backdrop of a huge global demand for innovative vaccines in this era, through continuous innovation and international cooperation, we will accelerate the commercialization of products in the global market, promote innovation in the entire value chain of the vaccine industry from R&D to commercialization, and create greater value for shareholders and investors. Today is the beginning of a brand-new journey for Recbio. I hope that all investors will continue to support our Company. Let's hope we will continue to move forward hand in hand, through the sweltering summer and winter, and create new glory together!"

About Recbio
Founded in 2012, Recbio is an innovative vaccine company with independent research and development technology as its core driving force. It is committed to building a full value chain of innovative vaccines, covering research and development, production and commercialization. The Company has always adhered to the mission of "creating first-class vaccines and protecting human health". With a strong research and development engine comprising of novel adjuvants, protein engineering, immunological evaluation and other core technology platforms, strategically focusing on disease areas with significant burden such as cervical cancers COVID-19, shingles, adult TB, HFMD and flu etc., the Company has established a high-value product pipeline consisting of 12 vaccine candidates with independent intellectual property rights, in order to meet the under-fulfilled public health needs. For more information, please visit https://www.recbio.cn/.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comOn March 31, the China-based novel vaccines company - Jiangsu Recbio Technology Co., Ltd. ("Recbio" or the "Company", Stock Code: 2179.HK) went public and was officially listed on the Hong Kong Stock Exchange.

SEMK (2250.HK) Announces 2021 Adjusted Net Profit Increases by Nearly 30% to HK$77 million, Becomes the Largest Domestic Character IP Company In China

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

HONG KONG, Mar 30, 2022 - (ACN Newswire) - SEMK Holdings International Limited ("SEMK", together with its subsidiaries, the "Group", stock code: 2250.HK), the largest domestic character Intellectual Property (IP) company* engaged in the provision of licensing services, design consultation services and retail of licensed brand products of its self-created B.Duck family characters, announced today the first annual results after its listing on the Main Board of The Stock Exchange of Hong Kong Limited on 17 January 2022.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Mr. Eddie Hui, Chairman and Chief Executive Officer of SEMK.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption
Together with its licensee, MADworld, SEMK launched its first drop of B. Duck NFT - 4,000 unique and original design 3D B.Duck NFTs as collectibles and potential future gaming celebrities.

Despite the unprecedented challenges due to the COVID-19 pandemic (the "Pandemic"), SEMK's business remains resilient. The Group's total revenue for the year ended 31 December 2021 ("FY2021" or the "Year") was approximately HK$290.0 million (FY2020: HK$233.5 million), representing a year-on-year growth of 24.2%. Excluding listing-expenses, the adjusted net profit for the Year was HK$77.3 million (FY2020: HK$59.8 million), representing a significant increase of 29.1% from the previous year.

The Board has resolved to declare a final dividend of HK$4.8 cents per ordinary share issued for the year ended 31 December 2021.

Mr. Eddie Hui, Chairman and Chief Executive Officer of SEMK, said, "It is an honor for me, for the first time as Chairman of SEMK, to relate to you our first annual results after listing. I am thrilled to announce that SEMK has become the largest domestic character IP company and ranked the fourth among all character IP companies in China, in terms of character licensing revenue in 2021*. It is our mission to be one of the pioneer Chinese character IP to expand in overseas so that can bring happiness and "Playful" lifestyle worldwide and empower soft power in Chinese cultural style. Indeed, the global licensing market is dominated by American and Japanese IPs, more than 60% of global retail sales of licensed goods attributable to North America. China only occupied less than 4% of global retail value of licensed products in 2021, which is not in same pace of global GDP sharing for China, this implies that the licensing market in China is in a very high growth potential. Our historical pace of growth is much faster than the overall growth rate of licensing market in China. Among other top 10 largest licensors in China, B.Duck is the youngest one and has demonstrated its high growth track records in the past years.

The listing of SEMK on the Main Board of the Hong Kong Stock Exchange in early 2022 is undoubtedly an important milestone for us. Looking forward, we will continue to adhere to our product-oriented development strategy, draw on our strong design capabilities and extensive licensees' network to bring more high-quality products to our fans."

Resilient Business Performance
The Group are principally engaged in two major businesses - character licensing business, as well as e-commerce and other business.

Character Licensing Business
The Group's character licensing business can be broadly divided into five service types, namely (i) merchandise licensing; (ii) location-based entertainment ("LBE") licensing; (iii) content and media licensing; (iv) promotion licensing; and (v) design consultation, which are interrelated and complementary to each other, with each of them being provided on a single, multi-service or integrated basis.

The Group's revenue from character licensing business increased by 69.9% to HK$166.6 million during the Year (FY2020: HK$98.0 million), mainly driven by the increase in excess royalties charged from the Group's licencees as a result of their increased sales of goods or services featuring the Group's IP characters. This segment accounted for 57.4% of the Group's total revenue in FY2021. The number of licencees (exclusive of licensing agents) the Group had increased to 385 as at the end of FY2021 (FY2020: 315).

E-commerce and Other Business
The Group' s e-commerce and other business mainly involve the sale of B.Duck family characters-featured products on e-commerce platforms of third parties and through offline sales channels. Seeing the potential synergies to be generated from the character licensing business, the Group began to explore the possibility of designing and selling its own products on e-commerce platforms. In 2015, SEMK launched its first online flagship store on Tmall, a well-known business to customer online shopping platform in China.

Following the success in the opening of such flagship store, the Group subsequently expanded onto other e-commerce platforms, such as JD.com, VIP.com and HKTVmall, to offer its products and allow customers to pay online with products directly shipped to the customers. During the Year, revenue from e-commerce and other business was approximately HK$123.4 million.

Launch of B. Duck NFTs and MOU with MADworld
With robust design capabilities and creativity, over the decades, the Group was able to ride on its self-create characters to launch various kind of licensed products in order to cope with changing consumption habits of B.Duck's fans. Recently, SEMK deployed a globalized business blueprint with an NFT "Non-fungible token" market. Joining hands with MADworld, the launch of B.Duck NFTs was a three-part series. The first drop, which was already launched, included 4,000 unique and original design 3D B.Duck NFTs as collectibles and potential future gaming celebrities. It was well received by the market and was sold out in 5 hours during the public session.

To facilitate strategic moves in this field in the future, SEMK has also entered into a memorandum of understanding (the "MOU") with MADworld Advisory Limited ("MADworld"), which specializes in development of licensed or licensable IPs into NFTs and other digital creatives, and marketing and offering to sell the same on platforms to be developed and/or accessed by such company. Pursuant to the MOU, SEMK and MADworld shall within two (2) months from the date of the MOU, enter into a joint venture agreement to establish a joint venture entity intended to be principally engaged in, amongst others, development of artworks and IPs owned by the Group into NFTs

Mr. Eddie Hui, Chairman and Chief Executive Officer of SEMK, concluded, "2021 was a peculiar year for us. Against the backdrop of the pandemic, thanks to the robust commitment of our team in delivering the strategic plans, we managed to sustain a resilient performance albeit the market challenges. The opportunities presented by the pandemic prompted us to make sufficient progress in online commercial operations, product flexibility, and B.Duck community online and offline digitalization integration.

Looking forward, through our strong fan base and coverage on social media-and e-commerce platforms, we will continue to accelerate the development of our product design capabilities in different territory, so as to expand to different variety licensing categories, including but not limited to LBE and digital assets projects. We will also proactively look for opportunities of strategic partnerships, alliances and acquisitions to facilitate sustainable business development."

About SEMK Holdings International Limited
SEMK Holdings International Limited (stock code: 2250.HK) is the largest domestic character IP company engaged in the provision of licensing services, design consultation services and retail of brand products of its self-created B.Duck family characters.

With strong in-house artistic design capabilities, SEMK has developed and nurtured a proprietary portfolio of approximately 26 self-created characters created under the motto of "Be Playful". As at 31 December 2021, B.Duck family characters had recorded in aggregate more than 10.5 million subscriptions or follows by B.Duck fans on various e-commerce platforms and social networking platforms, with in aggregate, over 740 million views of various types of content in relation to the elements of B.Duck family characters along with our "Be playful" motto.

Media Enquiries:
Strategic Financial Relations Limited
Heidi So Tel: (852) 2864 4826 Email: heidi.so@sprg.com.hk
Rachel Ko Tel: (852) 2114 2370 Email: rachel.ko@sprg.com.hk
Ivy Chan Tel: (852) 2864 4890 Email: ivy.chan@sprg.com.hk
Website: www.sprg.com.hk


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSEMK Holdings International Limited ("SEMK", together with its subsidiaries, the "Group", stock code: 2250.HK), the largest domestic character Intellectual Property (IP) company* engaged in the provision of licensing services

Blockpass, Lykke Partnership Integrates Zero Fees Exchange, Adds $PASS/USD

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

HONG KONG, Mar 29, 2022 - (ACN Newswire) - Blockpass is excited to announce that the long-standing association between Blockpass and cryptocurrency exchange Lykke will be strengthening. As the first step in this process, the PASS/ETH pair was delisted and replaced with the brand new opportunity of PASS/USD.

Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Lykke's mission is to build a new ecosystem for the outdated finance industry by leveraging the power of the blockchain. As a cryptocurrency exchange, Lykke has drawn acclaim and attention with its incredible zero trading fees and tiny buy-sell spreads for high-frequency trading. Catering to all types of clients in B2C and B2B markets - retail, API, business and others - Lykke has been a key player in the cryptocurrency exchange scene since its Lykke Wallet Cryptocurrency Exchange was launched in 2015. With no trading fees, no crypto deposit fees or limits, no inactivity fee and a solid base of liquidity, Lykke has been going from strength to strength. The zero-fee policy even applies to trading with bots used for algorithmic trading. Through its marketplace, Lykke offers unique financial products and empowers both retail customers and financial institutions to invest with no intermediaries, low cost and ease of use.

Blockpass is a digital identity verification provider which provides a one-click compliance gateway to financial services and other regulated industries. Through Blockpass, users can create, store, and manage a data-secure digital identity that can be used for an entire ecosystem of services, token purchases and access to regulated industries. For businesses and merchants, Blockpass is a comprehensive KYC & AML SaaS that requires no integration and no setup cost. You can set up a service in minutes, test the service for free and start verifying and on-boarding users. Currently with more than 500,000 verified user identity profiles, Blockpass facilitates instant onboarding, and to date over 3,000 services have taken advantage of this opportunity to get access to users with reusable digital identity profiles.

"Our work with Lykke goes all the way back to 2017 when Lykke was one of the first exchanges to list PASS," said Adam Vaziri, Blockpass CEO. "We've been looking forward to developing our relationship for a while and we're excited to provide a more current pair listing for PASS at the same time."

"We listed PASS back in 2017, inspired by the potential of the company and its vision. Since the beginning, we recognized the importance of KYC and AML compliance foreseeing the adoption of blockchain technology by masses and institutions. Since then, Blockpass has created a whole KYC ecosystem. We are excited to see this progress and happy to continue our collaboration," said Richard Olsen, Lykke CEO.

Blockpass has grown significantly in size and use since its inception, both in the number and range of users and organizations it has partnered with and the scope of its work. Blockpass continues to develop its digital identity protocol with updates and additions to improve the compliance experience. The existential need for DeFi projects to be regulatory compliant and the recent integrations have led to a surge in interest for Blockpass' On-chain KYC(TM) solution which promises to change the way blockchains enable compliance. Through its recent work with Animoca Brands, Blockpass is developing the ability to provide KYC where the delivery of the verification result is provably sent and shown on a blockchain without sharing the underlying data. This represents a significant step towards the future Blockpass hopes to bring about where identity verification can be proved without revealing any personal information at all.

About Blockpass
Blockpass, the pioneer of On-chain KYC(TM), is a fast, fully comprehensive KYC & AML screening software-as-a-service for blockchains, Crypto, Defi and other regulated industries. With Blockpass, you get an unmatched set of benefits for any compliance service that includes pay-as-you-go, no setup cost, no integration necessary, free testing, immediate launch and at the lowest cost. Blockpass' KYC Connect(TM) platform enables businesses to select requirements for customer onboarding that can include ID authentication, face-matching, address checking, AML ongoing monitoring and/or screening of sanctions lists, politically exposed persons (PEP), and adverse media. Through Blockpass, end-users easily create a verified portable identity that they can control and re-use to onboard with any service instantly. By integrating with Chainlink Network - a decentralized oracle solution - last year, Blockpass introduced the first On-chain KYC(TM) solution that will service many blockchains in the years to come. Additionally, Blockpass' partnership with Animoca Brands has demonstrated how verification and adherence to standards can be proved on a blockchain without revealing any underpinning data - a significant boon for verifying Animoca Brands' NFT prize winners and a huge step towards securing the ecosystem of the Metaverse. The Blockpass App is available from the App Store and Google Play.

For more information and updates, please visit and sign up to the following:
Promotional video: https://youtu.be/SvO2cw3e-SI
Website: https://www.blockpass.org/
PASS Token home: https://www.passtoken.org/
Email: sales@blockpass.org

About Lykke
Lykke is an umbrella name for a group of fintech companies with the headquarters in Switzerland and a subsidiary in the UK. The companies of the group operate on a B2B and B2P level and offer a wide range of products and services powered by blockchain technology. Lykke Core is the company based in the UK and running the Lykke Wallet zero fee cryptocurrency exchange. The trading platform was launched in 2015 and since then has gained the reputation of a reliable and secure trading venue with optimal trading conditions: 20+ assets, tight spreads, solid liquidity and zero trading and bank deposit/withdrawal fees. These conditions are the same for all kinds of traders independently of the volume they produce. The mission of the company is to truly democratize finance by creating a level playing field where the laymen have the same conditions that the whales enjoy in traditional finance. To start trading with these conditions just visit the company's website and get registered today. Apart from the cryptocurrency exchange, the group of companies produces and commercializes blockchain software solutions for governments and businesses, such as banks, financial service and product providers, and others. The role of Lykke Business, a Swiss entity within the group, is key in this aspect.

For more information please visit:
Lykke website: https://lykke.com
LB website: https://lykke-business.ch
Email: pr@lykke.com

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThis week, Blockpass is excited to announce that the long-standing association between Blockpass and cryptocurrency exchange Lykke will be strengthening. As the first step in this process, the PASS/ETH pair was delisted and instead replaced with the brand new opportunity of PASS/USD.

Gamerse: The NFT Gaming Industry’s First Unifying Social Hub

Gamerse: The NFT Gaming Industry's First Unifying Social Hub
As any lifelong gamer will tell you, gaming is a social experience. This rich social ecology allows NFT gamers to connect, trade, and learn about the fast-emerging blockchain gaming sector. The Social Aggregator Marketplace (SAM) is the initial component of Gamerse’s platform. Gamerse’s SAM is a cross-chain, cross-platform social center that curates, displays, and enables […]
Tag Template - News Hub PRO CoinGenius Hosts Virtual Crypto Event The Road To Mass Adoption

Recent articles

spot_img